Drugs / rhuCD40L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001145 | Oct 1999 → Oct 2003 | immunoproliferative disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhuCD40L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001145 ↗ |
| Action | Restore | “administration of rhuCD40L can reverse the core immunologic defects” NCT00001145 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human CD40 ligand (rhuCD40L)” NCT00001145 ↗ |
| Route | Subcutaneous | “rhuCD40L will be administered by injection under the skin” NCT00001145 ↗ |